A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis.

@article{Villanueva2001ARD,
  title={A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis.},
  author={A Villanueva and Eduardo G. Arathoon and Eduardo Gotuzzo and Rayanne S. Berman and Mark J. Dinubile and Carole A. Sable},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2001},
  volume={33 9},
  pages={
          1529-35
        }
}
  • A. Villanueva, E. Arathoon, C. Sable
  • Published 1 November 2001
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Caspofungin is a new broad-spectrum antifungal drug. A multicenter, double-blind, randomized trial was conducted to assess the efficacy, safety, and tolerability of caspofungin relative to amphotericin B in adults with endoscopically documented symptomatic Candida esophagitis. By use of a modified intent-to-treat analysis, endoscopically verified clinical success was achieved in 74% (95% confidence interval [CI], 59%-86%) and 89% (95% CI, 72%-98%) of patients receiving caspofungin at 50 and 70… 

Figures and Tables from this paper

A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis
TLDR
The safety and efficacy profile of caspofungin and micafungin in Japanese patients with fungal infections were directly compared in this prospective, randomized, double-blind study and the efficacy was similar.
Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
TLDR
Caspofungin was generally well tolerated in clinical trials; it had similar tolerability to intravenous fluconazole and was better tolerated than intravenous amphotericin B in these indications.
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
TLDR
Caspofungin is as effective as and generally better tolerated than liposomal amphotericin B when given as empirical antifungal therapy in patients with persistent fever and neutropenia.
A Multicenter, Open-Label Clinical Study of Micafungin (FK463) in the Treatment of Deep-seated Mycosis in Japan
TLDR
Treatment with micafungin as monotherapy seems to be effective and safe in patients with deep-seated mycosis and response rates for patients with prior antifungal treatment, which was considered ineffective or toxic.
Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole.
TLDR
Caspofungin appeared to be efficacious therapy for some patients with esophageal candidiasis who were clinically refractory to flu Conazole or infected by with reduced susceptibility to fluconazole in vitro.
Comparison of caspofungin and amphotericin B for invasive candidiasis.
TLDR
Caspofungin is at least as effective as amphotericin B for the treatment of invasive candidiasis and, more specifically, candidemia.
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
  • J. Maertens, I. Raad, T. Walsh
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2004
TLDR
Caspofungin demonstrated usefulness in the salvage treatment of IA and was observed in 37 (45%) of 83 patients, including 32 (50%) of 64 with pulmonary aspergillosis and 3 (23%) of 13 with disseminated asperGillosis.
COMPARISON OF CASPOFUNGIN AND AMPHOTERICIN B FOR INVASIVE CANDIDIASIS
TLDR
Caspofungin is at least as effective as amphotericin B for the treatment of invasive candidiasis and, more specifically, candidemia.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 42 REFERENCES
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.
  • T. Walsh, J. Hiemenz, E. Anaissie
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1998
TLDR
Findings support the use of ABLC in the treatment of invasive fungal infections in patients who are intolerant of or refractory to conventional antifungal therapy.
Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients.
TLDR
In conclusion, ABCD was safe and effective for treating immunocompromised patients with candidemia, and there were no significant changes in the levels of serum creatinine or bilirubin from baseline to the end of treatment.
Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS.
TLDR
The occurrence of candidal mucositis in patients receiving high doses of fluconazole is a matter of concern that requires further study in regard to the causes, prevention, and treatment of the disease.
Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain
TLDR
Two groups of recent clinical isolates of Candida albicans consisting of 101 isolates for which fluconazole MICs were < or = 0.5 microgram/ml and > or = 4.0 micrograms/ml were compared, finding isolates in general less susceptible to other azole drugs, but different patterns of decreased susceptibility were found.
Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients.
  • S. Revankar, O. Dib, T. Patterson
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1998
Signs and symptoms of oropharyngeal candidiasis (OPC) were correlated with microbiology and clinical response to fluconazole in a cohort of patients with advanced human immunodeficiency virus (HIV)
Treatment of murine Candida krusei or Candida glabrata infection with L-743,872
TLDR
P pneumocandin antifungal drug was evaluated in vivo in murine models of Candida krusei and Candida glabrata infection and was effective against both infecting isolates in immune-competent and immune-suppressed mice.
Correlation between In Vitro and In Vivo Antifungal Activities in Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis
TLDR
There is a strong correlation between in vitro fluconazole susceptibility by NCCLS methods and in vivo response to flu Conazole therapy of OPEC due to C. albicans, and it is concluded that there is an important advance in standardization of in vitro antifungal susceptibility methodology.
In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates
TLDR
Lipopeptide L-733,560 was the most active agent against C.albicans, with MICs for 50 and 90% of the strains tested of 0.01 and 0.06 microgram/ml, respectively.
Antifungal agents. Part I. Amphotericin B preparations and flucytosine.
  • R. Patel
  • Medicine, Biology
    Mayo Clinic proceedings
  • 1998
TLDR
Orally administered flucytosine is useful in certain infections, particularly cryptococcal meningitis, but it should be used with caution in patients with renal insufficiency.
...
1
2
3
4
5
...